TPWA
LGND icon

Twin Peaks Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-73
Closed -$14.6K – 1328
2026
Q1 		$14.6K Buy
+73
New +$14.4K ﹤0.01% 856
2025
Q3 		– Sell
-45
Closed -$6.87K – 1255
2025
Q2 		$6.87K Buy
+45
New +$4.81K ﹤0.01% 1131

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's LGND Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 73 shares — an estimated $14.6K sold.

Twin Peaks Wealth Advisors first reported a position in LGND in Q2 2025 and held it in 2 quarters. The position peaked at $14.6K in Q1 2026. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 73 Ligand Pharmaceuticals shares in Q2 2026, an estimated $14.6K.
  • Twin Peaks Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Ligand Pharmaceuticals position peaked at $14.6K in Q1 2026.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.